BSP's New Line of HyperQ Products: Bedside Ischemia Monitoring Systems Announces Successful Results of First Feasibility Study

Wednesday, February 27, 2008 General News J E 4
TEL AVIV, Israel, February 26 BSP (Biological SignalProcessing Ltd.) an Israeli company which develops and markets systems fornon-invasive diagnosis and monitoring of ischemic heart disease, announcessuccessful results in detecting ischemic events using its proprietary HyperQtechnology in resting conditions.

The successful results of the study indicate that the HyperQ(TM)technology, based on sophisticated analysis of high-frequency ECG components,can be implemented in two products: (i) bedside monitoring system for earlydetection of transient ischemic episodes and (ii) a resting ECG system forsensitive diagnosis of acute coronary syndrome, including myocardialinfarction. A highly important clinical application of these two devices isthe identification of heart attacks that are not accompanied by changes instandard ECG.

The results of the study showed that both HyperQ(TM) indices detectedischemia more accurately than ST analysis. Overall accuracy of HyperQ-basedanalysis was found to be 96% for the intensity-based index and 82% for themorphology-based index, both significantly higher than the accuracy of theconventional ST segment analysis at 75%.

"We are proud to present the first results that indicate clearly theHyperQ's strength in ischemia monitoring in a resting condition," said Dr.Amir Beker, Founder & CEO of BSP. "This carries an immense clinical value tocardiac patients, and marks the feasibility of BSP's next product line - themonitoring and resting HyperQ systems, which are planned to be offered to themarket by early 2009. BSP will launch the commercial introduction of theHyperQ(TM) Stress System in the US at the 57th ACC Meeting this March." addedDr. Beker.

About BSP

BSP is dedicated to providing novel, risk free and highly reliablesolutions for the diagnosis and monitoring of Ischemic Heart Disease. BSP'sHyperQ technology is implemented in cardiac systems that offer highlyreliable, low-cost and risk free cardiac monitoring and allows, for the firsttime, an effective diagnosis of Ischemic Heart Diseases in broad populations.BSP's HyperQ(TM) System for Stress Tests has received FDA clearance andobtained CE marking.

BSP was founded in 2000 by Dr. Amir Beker, and Ariel Landau, hadcompleted a successful IPO in mid-2006 and is traded on the Tel Aviv StockExchange.Contact: Dr. Amir Beker, +972-3-6474840

SOURCE BSP - Biological Signal Processing Ltd


You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
PayFlex Partners With Leading Health Education Com...
ZyGEM Launches prepGEM(TM) and forensicGEM(TM) DNA...